Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  


Syros Pharmaceuticals Inc

SYRS's Financial Statements and Analysis

Syros Pharmaceuticals Inc increased III. Quarter net loss per share of $-3.21 compare to net loss per share of $-0.41 recorded in the same quarter a year ago a decrease compare to $-0.54 realized in previous quarter.

III. Quarter
Earnings Per Share Revenues
$ -3.21 $  4 Mill
$-2.80     $-2M     -31.7 %

Syros Pharmaceuticals Inc 's Revenue fell by -31.7 % in III. Quarter (Sep 30 2022) year on year, to $4 million and declined by -38 % sequentially.

Syros Pharmaceuticals Inc is Expected to report next financial results on March 14, 2023.

More on SYRS's Income Statement

Syros Pharmaceuticals Inc 's in III. Quarter recorded net loss of $-30.253 million, an increase from net loss of $-26.027 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-34.481 million realized in previous quarter.

More on SYRS's Growth

SYRS's Cash flow In III. Quarter company's net cash flow was $112 million, capital expenditures fell by 5.81%, to $0 millions compare to same quarter a year ago and fell by 195.50% from II. Quarter (Jun 30 2022).

More on SYRS's Cash flow Statement

Syros Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Syros Pharmaceuticals Inc payed $ -12.21 cash per share, on a free-cash flow basis .